Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin

Life Sciences

Volumn 71, Issue 26, 2002, Pages 3109-3119

  Candussio, Luigi ^a   Decorti, Giuliana ^a   Crivellato, Enrico ^b   Granzotto, Marilena ^a   Rosati, Anna ^a   Giraldi, Tullio ^a   Bartoli, Fiora ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Doxorubicin; Normal tissues; P glycoprotein; Toxicity; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOXORUBICIN; GLYCOPROTEIN P; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; MALE; MICE; ORGAN SPECIFICITY; P-GLYCOPROTEIN; VERAPAMIL;

ANIMALIA;

EID: 0037111469     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02175-6     Document Type: Article

References (34)

1. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 1997;WB Saunders Co.
2. Pennock G.D., Dalton W.S., Roeske W.R., Appleton C.P., Mosley K., Plezia P., Miller T.P., Salmon S.E. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. Journal of the National Cancer Institute. 83(2):1991;105-110.
3. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology. 9(1):1991;17-24.
4. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. British Journal of Cancer. 68(4):1993;813-818.
5. Mross K., Hamm K., Hossfeld D.K. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemotherapy and Pharmacology. 31(5):1993;369-375.
6. Kerr D.J., Graham J., Cummings J., Morrison J.G., Thompson G.G., Brodie M.J., Kaye S.B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemotherapy and Pharmacology. 18(3):1986;239-242.
7. Cantwell B.M., Buamah P., Harris A.L. Phase I and II study of oral verapamil and intravenous vindesine. Proceedings of the American Society for Clinical Oncology. 42:1985;161.
8. Wilson W.H., Bates S.E., Fojo A., Bryant G., Zhan Z., Regis J., Wittes R.E., Jaffe E.S., Steinberg S.M., Herdt J.et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Journal of Clinical Oncology. 13(8):1995;1995-2004.
9. Wilson W.H., Jamis-Dow C., Bryant G., Balis F.M., Klecker R.W., Bates S.E., Chabner B.A., Steinberg S.M., Kohler D.R., Wittes R.E. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. Journal of Clinical Oncology. 13(8):1995;1985-1994.
10. Kroger N., Achterrath W., Hegewisch-Becker S., Mross K., Zander A.R. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treatment Reviews. 25(5):1999;279-291.
11. Lehnert M., Mross K., Schueller J., Thuerlimann B., Kroeger N., Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. British Journal of Cancer. 77(7):1998;1155-1163.
12. Sugawara I., Kataoka I., Morishita T., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Research. 48(7):1988;1926-1929.
13. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy for Science U S A. 86(2):1989;695-698.
14. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. Journal of Histochemistry and Cytochemistry. 38(9):1990;1277-1287.
15. Pearce H.L., Safa A.R., Bach N.J., Winter M.A., Cirtain M.C., Beck W.T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proceedings of the National Academy for Science U S A. 86(13):1989;5128-5132.
16. Mattern M.R., Hofmann G.A., Polsky R.M., Funk L.R., McCabe F.L., Johnson R.K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncology Research. 5(12):1993;467-474.
17. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Review of Biochemistry. 58:1989;137-171.
18. KrecicShepard M.E., Barnas C.R., Slimko J., Jones M.P., Schwartz J.B. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. Journal of Clinical Pharmacology. 40(3):2000;219-230.
19. AlvarezCedron L., Sayalero M.L., Lanao J.M. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. Journal of Chromatography B. 721(2):1999;271-278.
20. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy for Science U S A. 84(21):1987;7735-7738.
21. Singal P.K., Iliskovic N. Current concepts: Doxorubicin-induced cardiomyopathy. The New England Journal of Medicine. 339(13):1998;900-905.
22. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proceedings of the National Academy for Science U S A. 84(1):1987;265-269.
23. Sridhar R., Dwivedi C., Anderson J., Baker P.B., Sharma H.M., Desai P., Engineer F.N. Effects of verapamil on the acute toxicity of doxorubicin in vivo. Journal of the National Cancer Institute. 84(21):1992;1653-1660.
24. Bright J.M., Buss D.D. Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. Journal of the National Cancer Institute. 82(11):1990;963-964.
25. Mazue G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podesta A., Dellatorre P., Moneta D. Anthracyclines: A review of general and special toxicity studies (Clinical Study). International Journal of Oncology. 7(4):1995;713-726.
26. Nooter K., Oostrum R., Deurloo J. Effects of verapamil on the pharmacokinetics of daunomycin in the rat. Cancer Chemotherapy and Pharmacology. 20(2):1987;176-178.
27. Genne P., Coudert B., Pelletier H., Girardot C., Martin F., Chauffert B. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Research. 9(6):1989;1655-1659.
28. Van de Vrie W., Gheuens E.E., Durante N.M., De Bruijn E.A., Marquet R.L., Van Oosterom A.T., Eggermont A.M. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. Journal of Cancer Research and Clinical Oncology. 119(10):1993;609-614.
29. Horton J.K., Thimmaiah K.N., Houghton J.A., Horowitz M.E., Houghton P.J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochemical Pharmacology. 38(11):1989;1727-1736.
30. Payen L., Courtois A., Vernhet L., Guillouzo A., Fardel O. The multidrug resistance-associated protein (MRP) is over-expressed and functional in rat hepatoma cells. International Journal of Cancer. 81(3):1999;479-485.
31. Lautier D., Canitrot Y., Deeley R.G., Cole S.P.C. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochemical Pharmacology. 52(7):1996;967-977.
32. Finkel J.M., Knapp K.T., Mulligan L.T. Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats. Cancer Chemotherapy Reports. 53(3):1969;159-164.
33. Bachur N.R., Moore A.L., Bernstein J.G., Liu A. Tissue distribution and disposition of daunomycin (NSC-82151) in mice: fluorometric and isotopic methods. Cancer Chemotherapy Reports. 54(2):1970;89-94.
34. Bachur N.R. Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions. Journal of Pharmacology and Experimental Therapeutics. 177(3):1971;573-581.